Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women.
9 settembre 2016 aggiornato da: Hospital de Clinicas de Porto Alegre
Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women: a Randomized Controlled Clinical Trial.
This study aims to compare the effects of two water-based training models in physiological parameters of dyslipidemic elderly women.
Thus, a randomized controlled clinical trial will be conducted in parallel with the participation of 45 dyslipidemic elderly women.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The women will be randomly divided into three groups: water aerobics training (WA), resistance aquatic training (WR) and the third is the control group (who will perform relaxation sessions under water). The three groups will attend classes during 10 weeks, with two weekly sessions of 45 minutes each. The WA and WR groups will use the same four exercises in their training.
The WA group will be trained using the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
Will be measured, before and after the period of 10 weeks of intervention, biochemical, cardiorespiratory, neuromuscular and hemodynamic variables, parameters of quality of life and depressive symptoms in addition to the cardiovascular risk score of the participants of the three groups.
Data will be described by means values and lower and upper limits, with a 95% confidence interval. Comparisons between and within groups were performed using the method of generalized estimates of equations (GEE), with Bonferroni post hoc, adopting a 0.05 significance level.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
45
Fase
- Non applicabile
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 60 anni a 75 anni (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Femmina
Descrizione
Inclusion Criteria:
- being female, aged between 60 and 75, sedentary (not practicing any kind of regular, supervised physical activity in the last three months), have any type of dyslipidemia.
Exclusion Criteria:
- women who are smokers, suffering from cardiovascular disease with associated complications and those with orthopedic diseases that prevented the practice of systematic physical exercise, users of hormone therapy drugs and lipid-lowering medications.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: WA (Water Aerobics Training)
Water aerobics training.
|
The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
Altri nomi:
|
|
Sperimentale: WR (Water Resistance Training)
Resistance aquatic training.
|
The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
Altri nomi:
|
|
Comparatore attivo: CG (Control Group)
Control Group.
|
The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Total Cholesterol (TC) Change
Lasso di tempo: Change from baseline total cholesterol at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.
|
Change from baseline total cholesterol at 10 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Triglycerides (TG) Change
Lasso di tempo: Change from baseline triglycerides at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.
|
Change from baseline triglycerides at 10 weeks
|
|
High Density Lipoprotein (HDL) Change
Lasso di tempo: Change from baseline HDL at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.
|
Change from baseline HDL at 10 weeks
|
|
C-Reactive Protein (CRP) Change
Lasso di tempo: Change from baseline C-reactive protein at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the turbidimetric method in Cobas Mira Plus equipment, with the Biotechnical Kit for ultrasensitive C-reactive protein.
|
Change from baseline C-reactive protein at 10 weeks
|
|
Low Density Lipoprotein (LDL) Change
Lasso di tempo: Change from baseline LDL at 10 weeks
|
This variable will be estimated by Friedewald equation.
|
Change from baseline LDL at 10 weeks
|
|
Total Cholesterol/High Density Lipoprotein Ratio (TC/HDL ratio) Change
Lasso di tempo: Change from baseline TC/HDL at 10 weeks
|
This variable will be estimated by the simple division of variables.
|
Change from baseline TC/HDL at 10 weeks
|
|
Peak Oxygen Consumption (VO2peak) Change
Lasso di tempo: Change from baseline VO2peak at 10 weeks
|
This outcome will be measure through maximal progressive treadmill test, using the portable gas analyser VO2000 equipment.
|
Change from baseline VO2peak at 10 weeks
|
|
Oxygen Consumption at anaerobic threshold (VO2VT2) Change
Lasso di tempo: Change from baseline VO2VT2 at 10 weeks
|
This outcome will be measure through maximal progressive treadmill test, using the portable gas analyser VO2000 equipment.
|
Change from baseline VO2VT2 at 10 weeks
|
|
Heart Rate at anaerobic threshold (HRVT2) Change
Lasso di tempo: Change from baseline HRVT2 at 10 weeks
|
This outcome will be measure through maximal progressive treadmill test, using a heart rate monitor (POLAR, FT1).
|
Change from baseline HRVT2 at 10 weeks
|
|
Rest Heart Rate (HRrest) Change
Lasso di tempo: Change from baseline HRrest at 10 weeks
|
This outcome will be measure using a heart rate monitor (POLAR, FT1).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the heart rate.
|
Change from baseline HRrest at 10 weeks
|
|
Lipoprotein Lipase (LPL) Change
Lasso di tempo: Change from baseline LPL at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed using the LPL ELISA kit (Cell Biolabs).
The results will be read in a microplate reader (ELISA).
|
Change from baseline LPL at 10 weeks
|
|
Maximal dynamic muscle strength of knees extensors (MSKE) Change
Lasso di tempo: Change from baseline MSKE at 10 weeks
|
This outcome will be measured through the one-repetition maximal test (1RM).
|
Change from baseline MSKE at 10 weeks
|
|
Maximal dynamic muscle strength of knees flexors (MSKF) Change
Lasso di tempo: Change from baseline MSKF at 10 weeks
|
This outcome will be measured through the one-repetition maximal test (1RM).
|
Change from baseline MSKF at 10 weeks
|
|
Maximal dynamic muscle strength of horizontal shoulder flexors (MSHSF) Change
Lasso di tempo: Change from baseline MSHSF at 10 weeks
|
This outcome will be measured through the one-repetition maximal test (1RM).
|
Change from baseline MSHSF at 10 weeks
|
|
Rest Cardiac Output (COrest) Change
Lasso di tempo: Change from baseline COrest at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the cardiac output.
|
Change from baseline COrest at 10 weeks
|
|
Rest Stroke Volume (SVrest) Change
Lasso di tempo: Change from baseline SVrest at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the stroke volume.
|
Change from baseline SVrest at 10 weeks
|
|
Peak Cardiac Output (COpeak) Change
Lasso di tempo: Change from baseline COpeak at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment), during a maximal progressive treadmill test.
|
Change from baseline COpeak at 10 weeks
|
|
Peak Stroke Volume (SVpeak) Change
Lasso di tempo: Change from baseline SVpeak at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment), during a maximal progressive treadmill test.
|
Change from baseline SVpeak at 10 weeks
|
|
Rest Arterial Systolic Blood Pressure (SBPrest) Change
Lasso di tempo: Change from baseline SBPrest at 10 weeks
|
This outcome will be measured through blood pressure ambulatory monitor (Meditech, ABPM-04).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the arterial systolic blood pressure.
|
Change from baseline SBPrest at 10 weeks
|
|
Rest Arterial Diastolic Blood Pressure (DBPrest) Change
Lasso di tempo: Change from baseline DBPrest at 10 weeks
|
This outcome will be measured through blood pressure ambulatory monitor (Meditech, ABPM-04).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the arterial diastolic blood pressure.
|
Change from baseline DBPrest at 10 weeks
|
|
Cardiovascular Risk Score (CRS) Change
Lasso di tempo: Change from baseline cardiovascular risk score at 10 weeks
|
The Reynolds Risk Score Instrument will be used to estimate the cardiovascular risk.
|
Change from baseline cardiovascular risk score at 10 weeks
|
|
Quality of Life Change
Lasso di tempo: Change from baseline quality of life at 10 weeks
|
The quality of life will be estimated using the Whoqol-Bref instrument.
|
Change from baseline quality of life at 10 weeks
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Investigatori
- Investigatore principale: Ricardo Stein, Hospital de Clínicas de Porto Alegre
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 dicembre 2015
Completamento primario (Effettivo)
1 marzo 2016
Completamento dello studio (Effettivo)
1 maggio 2016
Date di iscrizione allo studio
Primo inviato
6 settembre 2016
Primo inviato che soddisfa i criteri di controllo qualità
9 settembre 2016
Primo Inserito (Stima)
14 settembre 2016
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
14 settembre 2016
Ultimo aggiornamento inviato che soddisfa i criteri QC
9 settembre 2016
Ultimo verificato
1 settembre 2016
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 14-0547
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
INDECISO
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .